Subject: Your Submission IPHM-D-17-00061R1
Date: Monday, 15 May 2017 at 12:01:49 British Summer Time
From: Inflammopharmacology (IPHM) (sent by em.iphm.0.53354c.7608a3fd@editorialmanager.com <em.iphm.0.53354c.7608a3fd@editorialmanager.com>)
To: Tambuwala, Murtaza
CC: khan-m8@email.ulster.ac.uk, m.lane@ucl.ac.uk, p.mccarron@ulster.ac.uk

Dear Dr Tambuwala,

Thank you for re-submitting the revised version your paper for consideration as a publication in Inflammopharmacology.
I am glad to inform you that the referees have recommended acceptance of your manuscript, and accordingly your paper will be published in the forthcoming issue of the journal. You should receive proofs in electronic pdf format shortly from the publishers, Springer Basel AG (Basel) Switzerland, through the editing and publications service, Spr Corrections. After checking or correcting these proofs they should be sent back to the publishers within 5 days of receipt. The corrected paper will then be immediately placed on the site for the journal which can be found at the publisher's website www.Springer.com/10787.
It is important that you should disclose if you have any Conflicts of Interest concerning this publication, and these should be stated at the end of the main text of the paper in proofstage.
The publication can then be cited as e-publication ahead of print with its own unique DoI identifier. The printed version of the paper will then appear in the Journal and a copy of this will be sent to you.
The publisher will send you copyright assignment and order forms for either electronic or paper copies of your paper of your choice.
All communications regarding the state of publication of your paper should now be directed to the production editor.

With best wishes,
Professor KD Rainsford, PhD, FRCPEdin, FRCPath, FRSC, FSB, FIBMS, Dr(hc)
Emeritus Professor of Biomedical Sciences
Editor-in-Chief, Inflammopharmacology
Biomedical Research Centre
Sheffield Hallam University
Howard Street
Sheffield, S1 1WB, UK
Direct Phone +44-114-225-3006
Email address for correspondence concerning the journal, Inflammopharmacology: editor@inflammopharmacology.com
Email address for general (non-journal) correspondence: k.d.rainsford@shu.ac.uk